摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-5-O-(tert-butyldimethylsilyl)dihydro-5-(hydroxymethyl)-2(3H)-furanone | 130767-09-8

中文名称
——
中文别名
——
英文名称
(R)-5-O-(tert-butyldimethylsilyl)dihydro-5-(hydroxymethyl)-2(3H)-furanone
英文别名
(5R)-5-(tert-Butyldimethylsiloxy)methyltetrahydrofuran-2-one;(R)-5-(((tert-butyldimethylsilyl)oxy)methyl)dihydrofuran-2(3H)-one;(R)-4-([(tert-butyldimethylsilyl)oxy]methyl)-4-butyrolactone;(5R)-5-[[tert-butyl(dimethyl)silyl]oxymethyl]oxolan-2-one
(R)-5-O-(tert-butyldimethylsilyl)dihydro-5-(hydroxymethyl)-2(3H)-furanone化学式
CAS
130767-09-8
化学式
C11H22O3Si
mdl
——
分子量
230.379
InChiKey
PUVKTUGKESTBDE-SECBINFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    284.8±13.0 °C(Predicted)
  • 密度:
    0.965±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.71
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:e814e5a8330b63787d90b090505fda11
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Convenient Synthesis of (3<i>S</i>,5<i>S</i>)-5-Hydroxy- and (3<i>R</i>,5<i>S</i>)-5-Chloropiperazic Acids of a Peptide Antibiotic, Monamycin G<sub>3</sub>
    作者:Reiko Ushiyama、Yasuchika Yonezawa、Chung-gi Shin
    DOI:10.1246/cl.2001.1172
    日期:2001.11
    Convenient synthesis of (3S,5S)-5-hydroxy- and (3R,5S)-5-chloropiperazic acids, which are the important constituting moieties of an antibiotic monamycin G3, and their possible stereoisomers constructing of similar antibiotics was achieved from D- and L-glutamic acids in short steps.
    (3S,5S)-5-羟基-和(3R,5S)-5-氯哌嗪酸是抗生素莫那霉素G3的重要组成部分,它们可能构建类似抗生素的立体异构体是从D-实现的。和 L-谷氨酸在短时间内。
  • A New approach to 1,7-dioxaspiro[5.5]undec-4-enes via metallated allenol ethers. Synthesis of Lacrimin A
    作者:Andrew Takle、Philip Kocieński
    DOI:10.1016/s0040-4020(01)85578-2
    日期:1990.1
    Key steps in the first total synthesis of Lacrimin A (2) include (a) the use of methoxyallene as an enone-1,3-dianion equivalent; (b) the use of a new copper-catalysed migratory insertion reaction to construct a tri-substituted alkene stereoselectively; and (c) the use of a Pd(O)-catalysed coupling reaction to generate an isochromanone ring.
    Lacrimin A(2)的第一个全合成过程中的关键步骤包括:(a)使用甲氧基烯丙烯作为烯酮-1,3-二价阴离子;(b)使用新的铜催化的迁移插入反应来立体选择性地构建三取代的烯烃;(c)使用Pd(O)催化的偶联反应产生异苯并二氢吡喃酮环。
  • L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents
    申请人:Yale University
    公开号:US05631239A1
    公开(公告)日:1997-05-20
    The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV.
    本发明涉及到一个惊人的发现,即某些二脱氧核苷类似物,其含有一个二脱氧核糖苷基团,该基团具有L构型(与天然的D构型相反),表现出出乎意料的对乙型肝炎病毒(HBV)的活性。特别地,本发明的化合物在与宿主细胞(即动物或人类组织)的毒性非常低的情况下,表现出对病毒复制的强效抑制。本发明的化合物主要用途是作为抑制HBV、HIV和其他逆转录病毒生长或复制的药剂,尤其是HBV。
  • L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and
    申请人:Yale University
    公开号:US05627160A1
    公开(公告)日:1997-05-06
    The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D-configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV. The compound 1-(2,3-dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine is shown to be a potent anti-HIV agent with low toxicity to host cells.
    本发明涉及一个惊人的发现,即某些二脱氧核苷类似物,其中包含具有L-构型(与自然存在的D-构型相反)的二脱氧核糖苷基团,表现出意外的对乙型肝炎病毒(HBV)的活性。特别是,本发明的化合物在与宿主细胞(即动物或人类组织)具有非常低的毒性的情况下,显示出对病毒复制的强效抑制。本发明的化合物主要用途是作为抑制HBV、HIV和其他逆转录病毒生长或复制的药剂,最好是抑制HBV。化合物1-(2,3-二脱氧-beta-L-核糖呋喃苷)-5-氟胞嘧啶被证明是一种对宿主细胞毒性低的强效抗HIV药物。
  • Method for treating HBV infections with
    申请人:Yale University
    公开号:US05561120A1
    公开(公告)日:1996-10-01
    The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV.
    本发明涉及一种惊人的发现,即某些含有L-构型(与天然存在的D-构型相反)的二脱氧核苷类似物,其含有二脱氧核糖苷基团,对乙型肝炎病毒(HBV)具有意想不到的活性。特别是,本发明的化合物在与宿主细胞(即动物或人类组织)的毒性非常低的情况下,表现出对病毒复制的强效抑制作用。本发明的化合物主要用作抑制HBV、HIV和其他逆转录病毒的生长或复制的药剂,其中最好是用于HBV的治疗。
查看更多